Phielix et al.: Hepatic Fat Content and Adipokines

German Diabetes Center

Status: Completed

Conditions: Type 2 Diabetes Mellitus

Treatments: Drug: Pioglitazone

Study type: Interventional

Funder types: Other

Identifiers

NCT01570660

026/2002

26/2002 (Registry Identifier)

Details and patient eligibility

About

Thiazoledinediones decrease blood glucose by their insulin-sensitizing properties. Here the investigators examined whether pioglitazone (PIO) improves insulin sensitivity independently of glycemic control and whether adipokines or non-esterfied fatty acids (NEFA) serve as mediators.

Enrollment: 24 patients

Sex: All

Ages: 45 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• well controlled patients with type 2 diabetes (Hb1Ac < 8%)
• no insulin therapy
• no co-morbidities
• stable medication use for the last 6 months
• stable body weight the last 6 months
• no diet in the last 6 months

Exclusion criteria

• Hb1Ac > 8%
• insulin therapy
• diabetes-related co-morbidities, like cardiovascular disease, neuropathology
• unstable medication use
• unstable body weight in the last 6 months (> 5 kg)
• following a diet in the last 6 months

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

24 participants in 1 patient group

control group

No Intervention group

Description:

parallel group without intervention

Treatment:

Drug: Pioglitazone